$IRLA Cashflow Statement | Understand Stock

$IRLA

$32.96 +$0.48 (1.48%) Close

$IRLA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net Loss
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash rent expense
Stock based compensation
Depreciation and amortization
Impairment loss on operating lease
Gain on sale of legacy assets
Loss on disposal of fixed assets
Change in the fair value of contingent consideration liabilities
Change in fair value of debt, net
Non-cash intangible impairment charge
Change in fair value of warrants
Non-cash goodwill impairment charge
Novosteo
Total non-cash goodwill impairment charge

Reclassification of cumulative translation adjustment to net income
Amortization of discount on available-for-sale investments
Change in deferred tax liabilities due to acquisition of Novosteo, Inc.
Change in deferred tax liabilities
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Novosteo
Total prepaid expenses and other current assets
Right of use assets, operating leases and operating lease liabilities
Other assets
Accounts payable
Accrued expenses and other current liabilities
Other liabilities
Net cash used in operating activities
Cash flow from investing activities:
Cash acquired from Novosteo, Inc.
Purchase of investments
Proceeds from maturities of investments
Advancement of note receivable
Cash paid in acquisition of EryDel S.p.A. net of cash acquired
Proceeds from disposal of assets
Purchase of property and equipment
Net cash provided by investing activities
Cash flows from financing activities:
Payment of contingent consideration
Proceeds from issuance of common stock, common warrants, and pre-funded warrants pursuant to private placement offering, net of issuance costs
Proceeds from issuance of common stock upon public offering, net of issuance costs
Proceeds from issuance of common stock upon exercise of stock options
Proceeds from issuance of common stock in connection with open market sales agreement, net of issuance costs
Proceeds from stock warrant exercise
Proceeds from initial public offering, net of stock offering costs
Proceeds from private placement offering, net of issuance costs
Payments of finance leases
Net cash provided by (used in) financing activities

Effect of exchange rate changes on cash
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of non-cash information:
Net assets acquired of EryDel S.p.A. in exchange for common stock
Ery Del
Novosteo
Total net assets acquired of EryDel S.p.A. in exchange for common stock

Right-of-use asset and operating lease liability reduction as a result of lease modification
Conversion of redeemable convertible preferred stock to common stock on initial public offering
Acceleration of vesting of redeemable convertible preferred stock on initial public offering
Interest payment on debt
Right-of-use assets obtained in exchange for new operating lease liabilities
Right-of-use asset and financing lease liability reduction as a result of lease modification

Comments